Proactive Investors - Run By Investors For Investors

AstraZeneca PLC wins Orphan Drug Designation for Fasenra to treat rare autoimmune disease

"We are exploring the potential of this medicine to address unmet medical needs in other eosinophil-driven diseases," said AstraZeneca
laboratory
EGPA can damage a patient’s lungs, skin, heart, gastrointestinal tract and nerves

AstraZeneca PLC said Monday the US Food and Drug Administration has granted Orphan Drug Designation for Fasenra to treat EGPA, a rare autoimmune disease that can damage multiple organs and tissues.

Eosinophilic Granulomatosis with Polyangiitis, or EGPA, can be fatal without treatment.  The disease can damage a patient’s lungs, skin, heart, gastrointestinal tract and nerves, and common symptoms include extreme fatigue, weight loss and muscle and joint pain.

READ: AstraZeneca in cancer drug setback

The regulatory agency’s Orphan Drug Designation program is aimed at helping to facilitate the development of drugs for rare diseases that affect fewer than 200,000 people in the US.  

EGPA is characterised by inflammation of blood vessels and elevated levels of eosinophils, a type of white blood cell. The drugmaker said Fasenra, an injectable treatment, is its first respiratory biologic and is currently approved as an add-on maintenance treatment for severe, eosinophilic asthma in the US, EU, Japan and several other jurisdictions.

Sean Bohen, AstraZeneca’s chief medical officer, said:  “Our clinical trials for Fasenra in severe, eosinophilic asthma show it depletes eosinophils and we are exploring the potential of this medicine to address unmet medical needs in other eosinophil-driven diseases."

There are few effective medicines for EGPA, AstraZeneca said in a statement. Patients are often treated with chronic high-dose oral corticosteroids and can experience recurrent relapses when trying to taper off the medication.

Phase III trials for Fasenra in EGPA have not started, the company said. AstraZeneca developed Fasenra with MedImmune, its global biologics research and development arm, and is in-licensed from BioWa Inc., a subsidiary of Kyowa Hakko Kirin Co. Ltd. In Japan.

 

View full AZN profile View Profile

AstraZeneca Timeline

Related Articles

parsortix
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
antibodies
May 02 2019
Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences
Surgery
February 20 2019
Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled last year to £11.6mln, up from £5.2mln a year earlier

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use